INTENSITY THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
INTENSITY THERAPEUTICS, INC. (INTS) reported Share-based Payment Arrangement, Expense of $387.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $387.00K, a 39.91% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $387.00K, a 11.03% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $450.00K, a 46.68% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $471.00K, a 2.48% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $2.00M, a 34.92% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $3.07M, a 119.81% increase from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $1.40M, a 19.59% increase from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $1.17M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $387.00K 10-Q · filed 2026-08-11 | $774.00K 10-Q · filed 2026-08-11 | $1.22M derived: sum of 3 quarters · filed 2026-08-11 | $1.70M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $387.00K 10-Q · filed 2026-05-07 | $837.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.31M derived: sum of 3 quarters · filed 2026-05-07 | $1.95M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $921.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.56M derived: sum of 3 quarters · filed 2026-08-11 | $2.00M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $471.00K 10-Q · filed 2025-11-06 | $1.11M derived: sum of 2 quarters · filed 2026-08-11 | $1.55M 10-Q · filed 2025-11-06 | $2.39M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $644.00K 10-Q · filed 2026-08-11 | $1.08M 10-Q · filed 2026-08-11 | $1.92M derived: sum of 3 quarters · filed 2026-08-11 | $2.41M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $435.00K 10-Q · filed 2026-05-07 | $1.28M derived: sum of 2 quarters · filed 2026-05-07 | $1.76M derived: sum of 3 quarters · filed 2026-05-07 | $2.35M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $844.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.33M derived: sum of 2 quarters · filed 2026-03-27 | $1.92M derived: sum of 3 quarters · filed 2026-03-27 | $3.07M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $483.00K 10-Q · filed 2025-11-06 | $1.07M derived: sum of 2 quarters · filed 2025-11-06 | $2.23M 10-Q · filed 2025-11-06 | $2.65M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $591.00K 10-Q · filed 2025-08-07 | $1.75M 10-Q · filed 2025-08-07 | $2.17M derived: sum of 3 quarters · filed 2025-08-07 | $2.52M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $1.16M 10-Q · filed 2025-05-13 | $1.58M derived: sum of 2 quarters · filed 2025-05-13 | $1.93M derived: sum of 3 quarters · filed 2025-05-13 | $2.24M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $774.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.09M derived: sum of 3 quarters · filed 2025-03-13 | $1.40M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $351.00K 10-Q · filed 2024-11-13 | $280.00K 10-Q · filed 2023-11-13 | $663.00K derived: sum of 2 quarters · filed 2024-11-13 | $975.00K 10-Q · filed 2024-11-13 | $761.00K 10-Q · filed 2023-11-13 | $1.71M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $312.00K 10-Q · filed 2024-08-08 | $240.00K 10-Q · filed 2023-08-14 | $624.00K 10-Q · filed 2024-08-08 | $481.00K 10-Q · filed 2023-08-14 | $1.36M derived: sum of 3 quarters · filed 2024-08-08 | $1.40M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $312.00K 10-Q · filed 2024-05-09 | $1.05M derived: sum of 2 quarters · filed 2024-05-09 | $1.09M derived: sum of 3 quarters · filed 2024-05-09 | $1.28M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $739.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $776.00K derived: sum of 2 quarters · filed 2024-03-14 | $972.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.17M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $37.00K 10-Q · filed 2023-11-13 | $233.00K derived: sum of 2 quarters · filed 2023-11-13 | $430.00K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $196.00K 10-Q · filed 2023-08-14 | $394.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |